Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 8/20 | 0.47 |
| ▸ | CTSL | P07711 | 3/20 | 0.47 |
| ▸ | CTSB | P07858 | 3/20 | 0.47 |
| ▸ | CTSD | P07339 | 2/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | ACACB | O00763 | 2/20 | 0.41 |
| ▸ | CTSK | P43235 | 6/20 | 0.41 |
| ▸ | DPP4 | P27487 | 1/20 | 0.41 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.40 |
| ▸ | CTSC | P53634 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.39 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.39 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18930496 | 0.91 | FPR1 (0.43) | CTSSCTSLCTSBATMCTSK | |
| SCHEMBL21169985 | 0.89 | P2RX7 (0.42) | CTSSCTSLCTSBATMACACB | |
| SCHEMBL18930237 | 0.86 | KDM4E (0.43) | CTSSCTSLCTSBCTSDATM | |
| SCHEMBL21144694 | 0.84 | DPP4 (0.46) | CTSSACACBDPP4CTSCKCNH2 | |
| SCHEMBL21144696 | 0.84 | DPP4 (0.46) | CTSSACACBDPP4CTSCKCNH2 | |
| SCHEMBL18930525 | 0.84 | ACACB (0.45) | CTSSCTSLCTSBCTSDATM | |
| SCHEMBL21144936 | 0.81 | ATM (0.52) | CTSSCTSLCTSBATMCTSK | |
| SCHEMBL18920601 | 0.81 | ATM (0.52) | CTSSCTSLCTSBATMCTSK | |
| SCHEMBL29163533 | 0.81 | ATM (0.52) | CTSSCTSLCTSBATMCTSK | |
| SCHEMBL18930231 | 0.80 | APP (0.51) | CTSSCTSLCTSBATMCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10654818-B2 | Furane derivatives as inhibitors of ATAD2 | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2020-05-19 | — | — | US | disclosed |
| EP-3383865-B1 | FURANE DERIVATIVES AS INHIBITORS OF ATAD2 | Bayer Pharma AG (DE) | 2020-01-29 | — | — | EP | disclosed |
| US-20190218196-A1 | FURANE DERIVATIVES AS INHIBITORS OF ATAD2 | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-07-18 | — | — | US | disclosed |
| WO-2017093272-A1 | FURANE DERIVATIVES AS INHIBITORS OF ATAD2 | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-06-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190218196-A1 | FURANE DERIVATIVES AS INHIBITORS OF ATAD2 | ATAD2, ATAD2B, TAF1L | CTSS 3972/4885CTSL 4617/4885CTSB 3425/4885 |
| US-10654818-B2 | Furane derivatives as inhibitors of ATAD2 | ATAD2, ATAD2B, TAF1L | CTSS 3972/4885CTSL 4617/4885CTSB 3425/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.